Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of “Moderate Buy” by Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $25.4444.

Several equities analysts have recently issued reports on the company. Piper Sandler decreased their price objective on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Weiss Ratings raised Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, April 21st. B. Riley Financial assumed coverage on Arcturus Therapeutics in a report on Wednesday, March 18th. They issued a “buy” rating and a $22.00 price objective for the company. Finally, Citigroup decreased their price objective on Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating for the company in a report on Thursday, March 5th.

Arcturus Therapeutics Stock Performance

Shares of ARCT stock opened at $7.16 on Wednesday. The stock’s 50-day simple moving average is $8.05 and its 200-day simple moving average is $7.42. The firm has a market capitalization of $203.49 million, a PE ratio of -2.55 and a beta of 2.36. Arcturus Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. The business had revenue of $2.06 million for the quarter, compared to analyst estimates of $6.30 million. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%. Sell-side analysts forecast that Arcturus Therapeutics will post -3.99 earnings per share for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

Large investors have recently bought and sold shares of the business. Osaic Holdings Inc. raised its holdings in Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 738 shares during the period. BNP Paribas Financial Markets raised its holdings in Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,586 shares during the period. Compagnie Lombard Odier SCmA acquired a new position in Arcturus Therapeutics in the 3rd quarter worth about $111,000. CANADA LIFE ASSURANCE Co raised its holdings in Arcturus Therapeutics by 27.5% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,567 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Arcturus Therapeutics by 42.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 2,313 shares during the period. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.